In silico method for identification of promising anticancer drug targets

SAR and QSAR in Environmental Research

Volumn 20, Issue 7-8, 2009, Pages 755-766

  Koborova, O N ^a   Filimonov, D A ^a   Zakharov, A V ^a   Lagunin, A A ^a   Ivanov, S M ^a   Kel, A ^b   Poroikov, V V ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b BIOBASE GMBH   (Germany)

Author keywords

Breast cancer; Drug target identification; Regulatory networks

Indexed keywords

DISEASE CONTROL; DISEASES; MOLECULAR BIOLOGY;

ANTICANCER DRUG; BREAST CANCER; DRUG TARGET IDENTIFICATION; DRUG TARGETS; FUNCTIONAL ORGANIZATION; GENOMICS/PROTEOMICS; IN-SILICO; POTENTIAL TARGETS; REGULATORY NETWORK; TRANSCRIPTOMICS;

PROTEINS;

EID: 72149104064     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/10629360903438628     Document Type: Article

References (26)

1. T.W. Hambley and W.N. Hait, Is anticancer drug development heading in the right direction?, Cancer Res. 69 (2009), pp. 1259-1262.
2. A. Burgun and O. Bodenreider, Accessing and integrating data and knowledge for biomedical research, Yearb Med Inform. (2008), pp. 91-101.
3. D. Ghosh and L.M. Poisson, ''Omics'' data and levels of evidence for biomarker discovery, Genomics 93 (2009), pp. 13-16.
4. R.M. Gutierrez-Rios, J.A. Freyre-Gonzalez, O. Resendis, J. Collado-Vides, M. Saier, and G. Gosset, Identification of regulatory network topological units coordinating the genome-wide transcriptional response to glucose in Escherichia coli, BMC Microbiol. 53 (2007), pp. 1-18.
5. A.L. Sellerio, B. Bassetti, H. Isambert, and M. Cosentino Lagomarsino, A comparative evolutionary study of transcription networks. The global role of feedback and hierachical structures, Mol. Biosyst. 5 (2009), pp. 170-179.
6. J.E. McDermott, R.C. Taylor, H. Yoon, and F. Heffron, Bottlenecks and hubs in inferred networks are important for virulence in Salmonella typhimurium, J. Comput. Biol. 16 (2009), pp. 169-180.
7. A. Ma'ayan, Insights into the organization of biochemical regulatory networks using graph theory analyses, J. Biol. Chem. 284 (2009), pp. 5451-5455.
8. H. Gea, H. Qian, and M. Qian, Synchronized dynamics and non-equilibrium steady states in a stochastic yeast cell-cycle network, Math. Biosci. 211 (2008), pp. 132-152.
9. W. Materi and D.S. Wishart, Computational systems biology in drug discovery and development: Methods and applications, Drug Discov. Today 12 (2007), pp. 295-303.
10. J. Tyson, K. Chen, and B. Novak, Network dynamics and cell physiology, Nature Rev. Mol. Cell. Biol. 2 (2001), pp. 908-916.
11. S. Braunewell and S. Bornholdt, Superstability of yeast cell cycle dynamics: Ensuring casuality in the presence of biochemical stochasticity, J. Theor. Biol. 245 (2006), pp. 638-643.
12. M. Krull, S. Pistor, N. Voss, A. Kel, I. Reuter, D. Kronenberg, H. Michael, K. Schwarzer, A. Potapov, C. Choi, O. Kel-Margoulis, and E. Wingender, TRANSPATH: An information resource for storing and visualizing signaling pathways and their pathological aberrations, Nucleic Acids Res. 34 (2006), pp. 546-551.
13. A. Kel, N. Voss, T. Valeev, P. Stegmaier, O. Kel-Margoulis, and E. Wingender, ExPlain: Finding upstream drug targets in disease gene regulatory networks, SAR QSAR Environ. Res. 19 (2008), pp. 481-494.
14. F. Kolpakov, V. Poroikov, R. Sharipov, Y. Kondrakhin, A. Zakharov, A. Lagunin, L. Milanesi, and A. Kel, CYCLONET - an integrated database on cell cycle regulation and carcinogenesis, Nucleic Acids Res. 35 (2007), pp. 550-556.
15. Y.V. Kondrakhin, R.N. Sharipov, A.E. Kel, and F.A. Kolpakov, Identification of differentially expressed genes by meta-analysis of microarray data on breast cancer, In Silico Biol. 8 (2008), pp. 383-411.
16. A.H. Wyllie, Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: An overview, Cancer Metastasis. 11 (1992), pp. 95-103.
17. P.S. Sharma, R. Sharma, and R. Tyagi, Inhibitors of Cyclin dependent kinases: Useful targets for cancer treatment, Curr. Cancer Drug Targets 8 (2008), pp. 53-75.
18. A. Singh, P. Greninger, D. Rhodes, L. Koopman, S. Violette, N. Bardeesy, and J. Settleman, A gene expression signature associated with ''K-Ras addiction'' reveals regulators of EMT and tumor cell survival, Cancer Cell. 15 (2009), pp. 489-500.
19. P. Ruzza, B. Biondi, and A. Calderan, Therapeutic prospect of Syk inhibitors, Expert Opin. Ther. Pat. 19(10) (2009), pp. 1-10.
20. J. Massague, G1 cell-cycle control and cancer, Nature 432 (2004), pp. 298-306.
21. M.B. Kastan and J. Bartek, Cell-cycle checkpoints and cancer, Nature 432 (2004), pp. 316-323.
22. A. Lindqvist, V. Rodriguez-Bravo, and R.H. Medema, The decision to enter mitosis: Feedback and redundancy in the mitotic entry network, J. Cell Biol. 185 (2009), pp. 193-202.
23. S. Gupta, G.E. Kass, E. Szegezdi, and B. Joseph, The mitochondrial death pathway: A promising therapeutic target in Diseases, J. Cell Mol Med. 13 (2009), pp. 1004-1033.
24. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak, Vascular endothelial growth factor (VEGF) and its receptors, FASEB J. 13 (1999), pp. 9-22.
25. Y. Zhang, H. Lu, P. Dazin, and Y. Kapila, Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: Fibronectin and integrin alphav mediate survival signals through focal adhesion kinase, J. Biol. Chem. 279 (2004), pp. 48342-48349.
26. S. Welch, H.W. Hirte, M.S. Carey, S.J. Hotte, M.S. Tsao, S. Brown, G.R. Pond, J.E. Dancey, and A.M. Oza, UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium, Gynecol. Oncol. 106 (2007), pp. 305-310.